Lorraine graduated with a BSc (Hons) 1st Class, Immunology and Pharmacology, from the University of Strathclyde, Glasgow, and went on to study for her PhD in the Department of Physiology and Pharmacology. On completion of her PhD Lorraine joined Professor Andrew Baker’s research group at the University of Glasgow and moved her research attention to gene delivery vectors. Lorraine’s research has focused on therapeutic intervention for cardiovascular disease using both pharmacological agents and gene delivery protocols. A central feature in both these disciplines is the relative lack of targeting capacity for either agent towards a specific disease site. Therefore, integral to her current research interests is the identification of novel targeting ligands which may subsequently be used to direct therapeutic intervention. Using phage display techniques in vitro, novel targeting peptides for vascular smooth muscle cells were identified and used to improve adenovirus (Ad) and adeno-associated virus (AAV) transduction in these cells. More recently, Lorraine used phage display in vivo to identify targeting peptides for distinct organs and successfully delivered peptide-modified AAV and pseudotyped Ad to chosen organs following systemic administration. Such advances in vector de-targeting and re-targeting may have important clinical implications for the future of gene therapy.